Background: The interindividual variability in motor response to DAergic drugs is a critical factor conditioning the long-term outcome of PD patients. This is particularly relevant for DA receptor agonists, which are commnonly prescribed as initial treatment in early PD. As yet, the genetic determinants of the response to ropinirole have not been investigated in PD patients.
Genetic polymorphism of DA receptors DRD2 and DRD3 and response to non-ergot DA agonist ropinirole in newly diagnosed PD patients / Calzetti, S; Mozzoni, P; Goldoni, M; Rossi, M; Negrotti, A.. - In: PARKINSONISM & RELATED DISORDERS. - ISSN 1873-5126. - 79:e30(2020).